Patents by Inventor Avi J. Ashkenazi

Avi J. Ashkenazi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of cancer using anti-Apo-2 antibodies
    Patent number: 7595046
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Grant
    Filed: December 9, 2005
    Date of Patent: September 29, 2009
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Avi J. Ashkenazi, Anan Chuntharapai, Kyung Jin Kim
  • Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
    Patent number: 7592439
    Abstract: A method of making monoclonal antibodies according to a mixed antigen immunization protocol is described. In addition, antibodies obtainable by the method are disclosed which specifically cross-react with two or more different receptors to which Apo-2 ligand (Apo-2L) can bind.
    Type: Grant
    Filed: April 24, 2007
    Date of Patent: September 22, 2009
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Anan Chuntharapai, K. Jin Kim
  • DcR3 polypeptide, A TNFR homolog
    Publication number: 20090191184
    Abstract: A TNFR homolog, identified as DcR3, is provided. Nucleic acid molecules encoding DcR3, chimeric molecules and antibodies to DcR3 are also provided.
    Type: Application
    Filed: October 14, 2008
    Publication date: July 30, 2009
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, David Botstein, Kelly H. Dodge, Audrey Goddard, Austin L. Gurney, Kyung Jin Kim, David A. Lawrence, Robert Pitti, Margaret A. Roy, Daniel B. Tumas, William I. Wood
  • COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
    Publication number: 20090186363
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: March 11, 2009
    Publication date: July 23, 2009
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Gretchen Frantz, Audrey Goddard, Lino Gonzalez, Austin L. Gurney, Paul Polakis, Andrew Polson, William I. Wood, Thomas D. Wu, Zemin Zhang
  • Apo-2 ligand
    Publication number: 20090186812
    Abstract: A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided.
    Type: Application
    Filed: September 28, 2006
    Publication date: July 23, 2009
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Ralph H. Schwall
  • Methods of using death receptor ligands and CD20 antibodies
    Publication number: 20090175854
    Abstract: Methods for using death receptor ligands, such as Apo-2 ligand/TRAIL polypeptides or death receptor antibodies, and CD20 antibodies to treat conditions such as cancer and immune related diseases are provided. Embodiments of the invention include methods of using Apo2L/TRAIL or death receptor antibodies such as DR5 antibodies and DR4 antibodies in combination with CD20 antibodies.
    Type: Application
    Filed: September 7, 2005
    Publication date: July 9, 2009
    Applicant: Genentech, Inc.
    Inventor: Avi J. Ashkenazi
  • Apo-2 ligand
    Publication number: 20090162364
    Abstract: A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided.
    Type: Application
    Filed: September 28, 2006
    Publication date: June 25, 2009
    Applicant: Genentech, Inc.
    Inventor: Avi J. Ashkenazi
  • Methods of Using Death Receptor Agonists and EGFR Inhibitors
    Publication number: 20090155247
    Abstract: Methods for using death receptor ligands, such as Apo-2 ligand/TRAIL polypeptides or death receptor antibodies, and EGFR inhibitors to treat pathological conditions such as cancer are provided. Embodiments of the invention include methods of using Apo2L/TRAIL or death receptor antibodies such as DR5 antibodies and DR4 antibodies in combination with EGFR inhibitors, such as Tarceva™.
    Type: Application
    Filed: February 16, 2006
    Publication date: June 18, 2009
    Inventor: Avi J. Ashkenazi
  • Methods for the diagnosis of tumors
    Patent number: 7547507
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: January 28, 2005
    Date of Patent: June 16, 2009
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Dan L. Eaton, Audrey Goddard, Austin L. Gurney, William I. Wood, Thomas D. Wu
  • COMPOSITIONS AND METHODS FOR TREATMENT OF NON-HODGKIN'S LYMPHOMA
    Publication number: 20090054631
    Abstract: The present invention is directed to compositions of matter useful for the treatment of non-Hodgkin's lymphoma in mammals and to methods of using those compositions for the same.
    Type: Application
    Filed: June 13, 2008
    Publication date: February 26, 2009
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Dylan L. Daniel, Theresa Shek
  • Apo-2L receptor agonist and CPT-11 synergism
    Publication number: 20090041788
    Abstract: Methods of using synergistically effective amounts of Apo-2L receptor agonists and CPT-11 to induce apoptosis and suppress growth of cancer cells, are provided.
    Type: Application
    Filed: October 14, 2008
    Publication date: February 12, 2009
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Mark Benyunes, Ralph Schwall
  • Assays and methods using biomarkers
    Publication number: 20090004204
    Abstract: Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of GalNac-T related molecules, such as GalNac-T14 or GalNac-T3, is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR5 agonist antibodies. Kits and articles of manufacture are also provided.
    Type: Application
    Filed: October 3, 2006
    Publication date: January 1, 2009
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Klaus W. Wagner
  • Methods and Compositions for Modulating Tweak and Fn14 Activity
    Publication number: 20080286271
    Abstract: Agonists and antagonists which modulate the activity of TWEAK and TWEAK receptor are provided. The methods, compositions and kits of the invention may be employed in the treatment of disorders such as cancer and immune-related diseases.
    Type: Application
    Filed: March 2, 2006
    Publication date: November 20, 2008
    Inventors: Avi J. Ashkenazi, Heather Maecker
  • Treatment of inflammatory bowel disease with IFN-? inhibitors
    Patent number: 7449176
    Abstract: The invention concerns a method for the prevention or treatment of inflammatory bowel disease by administering an interferon-? inhibitor. The invention further concerns pharmaceutical compositions and bispecific molecules useful in such method.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: November 11, 2008
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Rebecca H. R. Ward
  • Apo-2LI and Apo-3 polypeptides
    Publication number: 20080271167
    Abstract: Novel polypeptides, designated Apo-3 and Apo-2L1, involved in apoptosis are provided. Compositions including chimeric molecules, nucleic acids, and antibodies are also provided.
    Type: Application
    Filed: April 16, 2008
    Publication date: October 30, 2008
    Inventor: Avi J. Ashkenazi
  • Apo-2 ligand-anti-Her-2 antibody synergism
    Publication number: 20080241146
    Abstract: Methods of using synergistically effective amounts of Apo-2 ligand and anti-Her-2 antibodies to enhance cell death via apoptosis are provided.
    Type: Application
    Filed: October 25, 2007
    Publication date: October 2, 2008
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Gail Lewis Phillips
  • Apo-3 ligand polypeptide
    Publication number: 20080213837
    Abstract: A tumor necrosis factor and lymphotoxin homolog having apoptotic activity, identified as Apo-3 Ligand, is provided. Nucleic acid molecules encoding Apo-3 Ligand, chimeric molecules and antibodies to Apo-3 Ligand are also provided.
    Type: Application
    Filed: October 30, 2007
    Publication date: September 4, 2008
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Scot A. Marsters, Robert Pitti
  • Compositions and methods for treatment of non-Hodgkin's lymphoma
    Patent number: 7410772
    Abstract: The present invention is directed to compositions of matter useful for the treatment of non-Hodgkin's lymphoma in mammals and to methods of using those compositions for the same.
    Type: Grant
    Filed: June 30, 2005
    Date of Patent: August 12, 2008
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Dylan L. Daniel, Theresa Shek
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Publication number: 20080182275
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Application
    Filed: April 10, 2007
    Publication date: July 31, 2008
    Inventors: Avi J Ashkenazi, Kevin P. Baker, David Botstein, Luc Desnoyers, Dan L. Eaton, Napoleone Ferrara, Ellen Filvaroff, Sherman Fong, Wei-Qiang Gao, Hanspeter Gerber, Mary E. Gerritsen, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Kenneth J. Hillan, Ivar J. Kljavin, Sophia S. Kuo, Mary A. Napier, James Pan, Nicholas F. Paoni, Margaret Ann Roy, David L. Shelton, Timothy A. Stewart, Daniel Tumas, P. Mickey Williams, William I. Wood
  • Assays and methods using biomarkers
    Publication number: 20080182277
    Abstract: Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of GalNac-T related molecules, such as GalNac-T14 or GalNac-T3, is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR5 agonist antibodies. Kits and articles of manufacture are also provided.
    Type: Application
    Filed: October 3, 2006
    Publication date: July 31, 2008
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Klaus W. Wagner